Half or more of Americans with Alzheimer’s disease (AD) may not have received an appropriate diagnosis, particularly in cases that fall along the mild-to-moderate continuum. Although emerging evidence and an evolving understanding of AD progression have been incorporated into a 2011 update of diagnostic guidelines, identifying AD and distinguishing it from other disorders remain challenging, as in this case of a 58-year-old woman who complains of “memory issues.”
Neurologists and other clinicians who manage the care of patients with possible Alzheimer's disease or other dementias.
After taking part in this educational activity, participants should be better able to:
Describe the new construct for understanding, diagnosing, and treating Alzheimer’s disease (AD)
Apply contemporary approaches to the diagnosis of AD
Identify the role of AD biomarkers in preclinical and clinical settings
David A. Wolk, MD Assistant Professor Department of Neurology University of Pennsylvania Assistant Director, Penn Memory Center Philadelphia, PA
David A. Wolk, MD, has nothing to disclose.
Adam Fleisher, MD, MAS Geriatric Neurologist Associate Director of Brain Imaging Banner Alzheimer’s Institute Phoenix, AZ
Adam Fleisher, MD, MAS, is a consultant for Avid Radiopharmaceuticals, Eli Lilly and Co., Inc., and Merck & Co., Inc.
Gary J. Kennedy, MD Director, Division of Geriatric Psychiatry Montefiore Medical Center Bronx, NY
Gary J. Kennedy, MD, has nothing to disclose.
Accredited Provider Disclosures
The staff of the Center for Continuing Medical Education of Albert Einstein College of Medicine has nothing to disclose relative to this CME activity.
Publishing Staff Disclosures
Jill Rovitzky Black and Melissa A. Johnson, Haymarket Medical Education (HME), have nothing to disclose with regard to commercial support.
AMA PRA Category 1 Credit(s)TM
Albert Einstein College of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Albert Einstein designates this enduring educational activity for a maximum of 0.5 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
Disclosure of Unlabeled Use
This educational activity may contain discussion of approved and/or investigational uses of agents that are not indicated by the FDA. Albert Einstein College of Medicine of Yeshiva University, Lilly USA, LLC, and Haymarket Medical Education do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of Albert Einstein College of Medicine of Yeshiva University, Lilly USA, LLC, and Haymarket Medical Education. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
To obtain credit, a score of 70% or better is required. This CE is offered at no cost to participants. Please proceed with the activity until you have successfully completed this program, answered all test questions, completed the posttest survey, and have received your digital copy of your credit certificate. Your online certificate will be saved on myCME.com within your Profile/Exam History, which you can then access at any time.